pecified Drug-use Survey of Lotriga Granular Capsules: OCEAN3 (Outcome Prevention on Cardiovascular Events by Antihyperlipidemic Therapy With N3-fatty Acid in Japan)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Omega-3-acid ethyl esters (Primary)
- Indications Hyperlipidaemia
- Focus Therapeutic Use
- Acronyms OCEAN3
- Sponsors Takeda
- 14 Nov 2017 Planned primary completion date changed from 30 Sep 2019 to 31 Dec 2019.
- 14 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Nov 2017 Planned number of patients changed from 14000 to 15331.